Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats

References

• Briganti A, Capitanio U, Suardi N, et al. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl. 2009;8(13):865–871. doi:10.1016/j.eursup.2009.11.002
   Web of Science ®Google Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20(Suppl 3):S11–S18. doi:10.1038/ijir.2008.55
   PubMed Web of Science ®Google Scholar
• Wang L, Xie L, Tintani F, et al. Aberrant transforming growth factor-beta activation recruits mesenchymal stem cells during prostatic hyperplasia. Stem Cells Transl Med. 2017;6(2):394–404. doi:10.5966/sctm.2015-041128191756
   PubMedGoogle Scholar
• Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1784–1791.15540721
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13(10):613–626. doi:10.1038/nrurol.2016.16827686153
   PubMed Web of Science ®Google Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–1216. doi:10.1016/j.eururo.2006.12.01117182170
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate. 1996;28(6):392–405. doi:10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C8650077
   PubMed Web of Science ®Google Scholar
• Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996;27(7):668–675.8698310
   PubMed Web of Science ®Google Scholar
• Descazeaud A, Weinbreck N, Robert G, et al. Transforming growth factor β‐receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int. 2011;108(2b):E23–E28. doi:10.1111/j.1464-410X.2010.09699.x20840324
   PubMedGoogle Scholar
• Sciarra A, Voria G, Mariotti G, Gentile V, Pastore A, Di Silverio F. Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia: clinical implications. Urol Int. 2002;69(4):253–262. doi:10.1159/00006612812444279
   PubMedGoogle Scholar
• Bullock TL, Andriole GL Jr. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs. 2006;11(1):111–123. doi:10.1517/14728214.11.1.11116503830
   PubMedGoogle Scholar
• McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007;29(3):387–398.17577460
   PubMed Web of Science ®Google Scholar
• Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α‐reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–884. doi:10.1111/j.1743-6109.2010.02157.x21176115
   PubMed Web of Science ®Google Scholar
• Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. Integr Biol. 2014;6(1):9–26. doi:10.1039/c3ib40165k
   Google Scholar
• Bhattacharya R, Mukherjee P. Biological properties of “naked” metal nanoparticles. Adv Drug Deliv Rev. 2008;60(11):1289–1306. doi:10.1016/j.addr.2008.03.01318501989
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011;7(5):580–587. doi:10.1016/j.nano.2011.01.01121333757
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013;110(17):6700–6705. doi:10.1073/pnas.121454711023569259
   PubMedGoogle Scholar
• Tsai CY, Shiau AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum. 2007;56(2):544–554. doi:10.1002/art.2240117265489
   PubMedGoogle Scholar
• Mukherjee P, Bhattacharya R, Wang P, et al. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005;11(9):3530–3534. doi:10.1158/1078-0432.CCR-04-248215867256
   PubMed Web of Science ®Google Scholar
• Kalishwaralal K, Sheikpranbabu S, BarathManiKanth S, Haribalaganesh R, Ramkumarpandian S, Gurunathan S. Gold nanoparticles inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells. Angiogenesis. 2011;14(1):29–45. doi:10.1007/s10456-010-9193-x21061058
   PubMedGoogle Scholar
• Sumbayev VV, Yasinska IM, Garcia CP, et al. Gold nanoparticles downregulate interleukin‐1β‐induced pro‐inflammatory responses. Small. 2013;9(3):472–477. doi:10.1002/smll.20120152823112137
   PubMed Web of Science ®Google Scholar
• Roa W, Zhang X, Guo L, et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology. 2009;20(37):375101. doi:10.1088/0957-4484/20/37/37510119706948
   PubMed Web of Science ®Google Scholar
• Reznikov AG, Salivonyk OA, Sotkis AG, Shuba YM. Assessment of gold nanoparticle effect on prostate cancer LNCaP cells. Exp Oncol. 2015;37(2):100–104.26112935
   PubMedGoogle Scholar
• Aljabali AA, Akkam Y, Al Zoubi MS, et al. Synthesis of gold nanoparticles using leaf extract of ziziphus zizyphus and their antimicrobial activity. Nanomaterials. 2018;8(3):174. doi:10.3390/nano8030174
   Web of Science ®Google Scholar
• Zuber A, Purdey M, Schartner E, et al. Detection of gold nanoparticles with different sizes using absorption and fluorescence based method. Sens Actuators B Chem. 2016;227:117–127. doi:10.1016/j.snb.2015.12.044
   Web of Science ®Google Scholar
• Zhang X, Zhang Q, Zhang Z, Na Y, Guo Y. Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition. Urology. 2006;68(4):905–910. doi:10.1016/j.urology.2006.05.01317070390
   PubMedGoogle Scholar
• Al-Trad B, Al-Zoubi M, Qar J, et al. Inhibitory effect of thymoquinone on testosterone-induced benign prostatic hyperplasia in wistar rats. Phytother Res. 2017;31(12):1910–1915. doi:10.1002/ptr.593628960541
   PubMedGoogle Scholar
• Huang X, Lee C. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta. Front Biosci. 2003;8:s740–s749.12957826
   PubMed Web of Science ®Google Scholar
• Hu S, Yu W, Lv T-J, Chang C-S, Li X, Jin J. Evidence of TGF-β 1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells. Mol Membr Biol. 2014;31(2–3):103–110. doi:10.3109/09687688.2014.89421124650126
   PubMed Web of Science ®Google Scholar
• Alonso-Magdalena P, Brossner C, Reiner A, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A. 2009;106(8):2859–2863. doi:10.1073/pnas.081266610619196965
   PubMedGoogle Scholar
• Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009;69(16):1774–1780. doi:10.1002/pros.2102719670242
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112(4):432–441. doi:10.1111/bju.1211823650937
   PubMed Web of Science ®Google Scholar
• Chen H, Dorrigan A, Saad S, Hare DJ, Cortie MB, Valenzuela SM. In vivo study of spherical gold nanoparticles: inflammatory effects and distribution in mice. PLoS One. 2013;8(2):e58208. doi:10.1371/journal.pone.005820823469154
   PubMed Web of Science ®Google Scholar
• Khan HA, Abdelhalim MA, Alhomida AS, Al-Ayed MS. Effects of naked gold nanoparticles on proinflammatory cytokines mRNA expression in rat liver and kidney. Biomed Res Int. 2013;2013:590730. doi:10.1155/2013/59073023781503
   PubMedGoogle Scholar
• Li WQ, Wang F, Liu ZM, Wang YC, Wang J, Sun F. Gold nanoparticles elevate plasma testosterone levels in male mice without affecting fertility. Small. 2013;9(9‐10):1708–1714. doi:10.1002/smll.20120107922911975
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond). 2016;11(6):673–692. doi:10.2217/nnm.16.527003448
   PubMed Web of Science ®Google Scholar